Investigation of the PADA as a method for monitoring: GPIIb/IIIa inhibitors and other antiplatelet agents

Seminars in Thrombosis and Hemostasis

Volumn 31, Issue 4, 2005, Pages 482-485

  Graff, Jochen ^a   Harder, Sebastian ^a,b  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^b Department of Clinical Pharmacology ^*

Author keywords

Aspirin; GPIIb IIIa inhibitor; Monitoring; P2y12 inhibitor; Platelet function assay

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; AR C 69931MX; CITRIC ACID; CLOPIDOGREL; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; HIRUDIN; UNCLASSIFIED DRUG;

ADULT; BLOOD SAMPLING; CONCENTRATION RESPONSE; CONFERENCE PAPER; DRUG EFFECT; DRUG MONITORING; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; NORMAL HUMAN; PRIORITY JOURNAL; RECEPTOR UPREGULATION; SENSITIVITY AND SPECIFICITY; THROMBOCYTE ADHESION;

ADENOSINE MONOPHOSPHATE; ANTIBODIES, MONOCLONAL; ANTICOAGULANTS; ASPIRIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG MONITORING; HIRUDINS; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; PEPTIDES; PLATELET ADHESIVENESS; PLATELET AGGREGATION INHIBITORS; PLATELET FUNCTION TESTS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; SENSITIVITY AND SPECIFICITY; TICLOPIDINE;

EID: 25444508270     PISSN: 00946176     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2005-916685     Document Type: Conference Paper

References (10)

1. McKenzie ME, Gurbel PA, Levine DJ, Serebruany VL. Clinical utility of available methods for determining platelet function. Cardiology 1999;92:240-247
2. Harder S, Klinkhardt U, Graff J, et al. In vitro dose response to different GPIIb/IIIa antagonists: inter-laboratory comparison of various platelet function tests. Thromb Res 2001;102:39-48
3. [No authors listed.]. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. The EPILOG Investigators. N Engl J Med 1997;336:1689-1696
4. Michelson AD. Flow cytometric analysis of platelets. Vox Sang 2000;78:137-142
5. Kereiakes DJ, Mueller M, Howard W, et al. Efficacy of abciximab induced platelet blockade using a rapid point of care assay. J Thromb Thrombolysis 1999;7:265-276
6. Steinhubl SR. Assessing the optimal level of platelet inhibition with GPIIb/IIIa inhibitors in patients undergoing coronary intervention. Rationale and design of the GOLD study. J Thromb Thrombolysis 2000;9:199-205
7. Harrington RA, Kleiman NS, Kottke-Marchant K, et al. Immediate and reversible platelet inhibition after intravenous administration of a peptide glycoprotein IIb/IIIa inhibitor during percutaneous coronary intervention. Am J Cardiol 1995;76:1222-1227
8. Storey RF, Newby LJ, Heptinstall S. Effects of P2Y(1) and P2Y(12) receptor antagonists on platelet aggregation induced by different agonists in human whole blood. Platelets 2001;12:443-447
9. Marciniak SJ Jr, Jordan RE, Mascelli MA. Effect of Ca2+ chelation on the platelet inhibitory ability of the GPIIb/IIIa antagonists abciximab, eptifibatide and tirofiban. Thromb Haemost 2001;85:539-543
10. Phillips DR, Teng W, Arfsten A, et al. Effect of Ca2+ on GP IIb-IIIa interactions with integrilin: enhanced GP IIb-IIIa binding and inhibition of platelet aggregation by reductions in the concentration of ionized calcium in plasma anticoagulated with citrate. Circulation 1997;96:1488-1494